0001772028-19-000002.txt : 20190808 0001772028-19-000002.hdr.sgml : 20190808 20190807182427 ACCESSION NUMBER: 0001772028-19-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190808 DATE AS OF CHANGE: 20190807 EFFECTIVENESS DATE: 20190808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scopus BioPharma Inc. CENTRAL INDEX KEY: 0001772028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821248020 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-346042 FILM NUMBER: 191006877 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE, SUITE 300 CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: (212) 479-2513 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE, SUITE 300 CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: Scopus Biopharma Inc. DATE OF NAME CHANGE: 20190327 D 1 primary_doc.xml X0708 D LIVE 0001772028 Scopus BioPharma Inc. 420 LEXINGTON AVENUE SUITE 300 NEW YORK NY NEW YORK 10170 (917) 674-3889 DELAWARE Project18 Inc. Scopus Biopharma Inc. Corporation true 2017 Morris C. Laster 420 Lexington Avenue Suite 300 New York NY NEW YORK 10170 Executive Officer Director Co-Chairman, Chief Executive Officer and Director Joshua R. Lamstein 420 Lexington Avenue Suite 300 New York NY NEW YORK 10170 Executive Officer Director Co-Chairman and Director Robert J. Gibson 420 Lexington Avenue Suite 300 New York NY NEW YORK 10170 Executive Officer Director Vice Chairman, Secretary, Treasurer and Director Ira Scott Greenspan 420 Lexington Avenue Suite 300 New York NY NEW YORK 10170 Director Director Pharmaceuticals No Revenues 06b false 2019-07-25 false true true true false 0 HCFP/Capital Markets LLC 149111 None None 747 Third Avenue Floor 2 New York NY NEW YORK 10017 AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA GA GEORGIA IL ILLINOIS IN INDIANA KY KENTUCKY MD MARYLAND MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OH OHIO TX TEXAS UT UTAH VA VIRGINIA false 600000 450507 149493 false 17 45050 0 The placement agent is entitled to a fee equal to 8% of the gross proceeds of this offering. In addition, a non-accountable expense allowance of 2% of funds raised will be paid to placement agent. 0 false Scopus BioPharma Inc. Joshua R. Lamstein Joshua R. Lamstein Co-Chairman 2019-08-07